Several reports indicate that factors enhancing glucose uptake and glycolytic flux (e.g., Wnt3a) [51–52] or downregulating mitochondrial OP (e.g., soluble APP) [53] could be beneficial in AD. This evidence concerns the gene WNT3A and Alzheimer disease.